Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.74 |
| ▸ | WNT3A | P56704 | 2/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4336989 | 0.90 | MAPK14 (0.75) | MAPK14 | |
| SCHEMBL4332734 | 0.89 | MAPK14 (0.87) | MAPK14PRKACAROCK1ALDH1A1POLB | |
| SCHEMBL1878101 | 0.88 | MAPK14 (0.76) | MAPK14WNT3APRKACAROCK1 | |
| SCHEMBL4340549 | 0.88 | MAPK14 (0.85) | MAPK14WNT3APRKACAROCK1 | |
| SCHEMBL4342410 | 0.88 | MAPK14 (0.74) | MAPK14PRKACAROCK1ALDH1A1POLB | |
| SCHEMBL4334630 | 0.87 | MAPK14 (0.64) | MAPK14 | |
| SCHEMBL4327728 | 0.87 | MAPK14 (0.79) | MAPK14PRKACAROCK1 | |
| SCHEMBL4342424 | 0.87 | MAPK14 (0.73) | MAPK14PRKACAROCK1ALDH1A1POLB | |
| SCHEMBL4339268 | 0.85 | MAPK14 (0.74) | MAPK14PRKACAROCK1ALDH1A1POLB | |
| SCHEMBL4328430 | 0.85 | MAPK14 (0.80) | MAPK14PRKACAROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| CN-101472921-A | Pyridylisoxazole derivative | ASKA PHARM CO LTD (JP) | 2009-07-01 | — | — | CN | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MAPK14 43/4885WNT3A 1703/4885PRKACA 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.